Archive: Company News
Neonatal Diagnostics Company InfanDx AG Completes Series A Funding
— Company raises EUR 4 million to reach key value-creating milestones over the next 12-18 months
— Klaus Albrecht, Alluti GmbH, appointed as new member of the Supervisory Board
InfanDx AG (Cologne, Germany), a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced a first closing of a Series A financing round raising EUR 4 million from new and existing investors.
T-knife Therapeutics Announces the Appointment of Megan Baierlein as Chief Operating Officer
T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the appointment of Megan Baierlein as chief operating officer.
“We are excited to welcome Megan to our executive leadership team,” stated Thomas M. Soloway, chief executive officer of T-knife. “Megan has over two decades of experience building and leading successful life sciences companies, overseeing strategic planning, program management, and clinical operations functions. We look forward to the significant contributions that Megan will bring to T-knife as we advance our lead candidate TK-8001, targeting MAGE-A1 positive solid tumors, toward the clinic later this year and continue to advance our leading pipeline of novel TCR-T product candidates.”
Eisbach Bio Receives EUR 8 Million Government Grant to Progress COVID-19 Antiviral Through Phase I/II Clinical Development
Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, today announced additional financial support from the German Ministry for Education and Research (BMBF) for the clinical development of its first-in-class SARS-CoV-2 helicase inhibitor. The total funding of EUR 8 million will support the clinical development of the Company’s novel COVID-19 therapeutic following the recent completion of its preclinical development.
Adept Neuro Reaches Key Milestone in the Development of Novel Intracerebral Stereoelectroencephalography (SEEG) Electrodes
— Second investment tranche provided by DIXI medical
— Preparation of regulatory certifications and market launch
Adept Neuro SA (Lausanne, Switzerland), a joint venture of DIXI Medical (Le Locle, Switzerland, and Besançon, France) and Aleva Neurotherapeutics SA (Lausanne, Switzerland) developing a new generation of intracerebral stereoelectroencephalography (SEEG) electrodes facilitating localization and thermocoagulation of the epileptogenic zones, today announced that it has reached a significant milestone in the development of MEMS-enabled smart SEEGs electrodes. MEMS are micro-electro-mechanical systems allowing for miniaturization and great flexibility of design.